Q1 2018 13F Holders as of 3/31/2018
-
Type / Class
-
Equity / COM
-
Number of holders
-
71
-
Total 13F shares, excl. options
-
25.9M
-
Shares change
-
-504K
-
Total reported value, excl. options
-
$189M
-
Value change
-
-$4.82M
-
Put/Call ratio
-
1.39
-
Number of buys
-
32
-
Number of sells
-
-32
-
Price
-
$7.29
Significant Holders of AVADEL PHARMACEUTICALS - COM (AVDL) as of Q1 2018
91 filings reported holding AVDL - AVADEL PHARMACEUTICALS - COM as of Q1 2018.
AVADEL PHARMACEUTICALS - COM (AVDL) has 71 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 25.9M shares
.
Largest 10 shareholders include BRANDES INVESTMENT PARTNERS, LP (4.81M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (3.79M shares), Broadfin Capital, LLC (2.62M shares), ARMISTICE CAPITAL, LLC (1.84M shares), ACADIAN ASSET MANAGEMENT LLC (1.65M shares), PERCEPTIVE ADVISORS LLC (1.3M shares), DEUTSCHE BANK AG\ (1.24M shares), MORGAN STANLEY (1.13M shares), BROWN CAPITAL MANAGEMENT LLC (913K shares), and Ghost Tree Capital, LLC (850K shares).
This table shows the top 71 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.